• Small sample volume required (2 µl)
• High density (simultaneously detect 33 autoantibodies)
• High sensitivity
• Large dynamic range
• Suitable for high-throughput assays
• High efficiency and accuracy
• Affordable, quick and simple to use
• Customizable: Tell us the autoimmunogens you're interested in

The following Figure 1 represents a typical result using serum on the RayBio^® Autoimmune Disease IgG Autoantibody Detection Array (Cat #. PAH-AIDG-G1). The protein arrays were incubated with 200-fold diluted serum samples from normal individuals and patients with different autoimmune diseases. After washing steps, the arrays were sequentially incubated with biotin-labeled anti-human IgG antibody and fluorescent dye-labeled streptavidin. The signals from the bound autoantibodies were captured with a fluorescence scanner.

Sample diluent alone (Figs. 1A & 1B) and normal sera (Figs. 1C & 1D) were used as negative controls, and the arrays signals indicate that no significant background occurred. In some cases, a negligible signal can be observed, which may be caused by non-specific binding derived from the biotin-labeled anti-human IgG antibody and/or fluorescent dye-labeled streptavidin. However, these weak background signals will be subtracted in subsequent data analysis procedures and will not affect sample test results. A strong binding signal was detected in multiple targets among different autoimmune disease patients: systemic lupus erythematosus (Figs.1E & 1F), Sjøgren's syndrome (Figs.1G & 1H), system vasculitis (Figs.1I & 1J), and primary biliary cirrhosis (Figs.1K & 1L).

Fig 1. Typical result using serum on the RayBio^® Autoimmune Disease IgG Autoantibody Detection Array. The protein arrays were incubated with diluent alone (A, B), diluted serum samples derived from normal individuals (C, D) and those from various autoimmune disease patients (E-L). Yellow boxes, show various controls as indicated (biotin-labeled BSA, human IgG and IgA).